"Blood-Based Test for Colorectal Cancer Shows High Accuracy, Driving Surge in Exact Sciences Stock"
Exact Sciences stock surged to a seven-month high after Freenome revealed results of a study on its blood-based colon cancer test, which showed similar specificity but lower sensitivity compared to Exact's Cologuard. Analysts believe the results dispel concerns about blood-based tests replacing stool-based ones and expect Exact Sciences shares to trade on a fundamental basis going forward. Despite the stock's recent climb, Freenome could still improve its test's sensitivity for advanced adenomas.